phase III
Lilly/Incyte RA drug bests Humira in Phase III trial
November 10, 2015Research and Development Humira, baricitinib, lilly, phase III, rheumatoid arthritis
Eli Lilly says its investigational therapy baricitinib outperformed AbbVie’s Humira after 12 weeks in a late-stage study of people with …
Otsuka, GW announce Sativex fails in Phase III cancer pain trials
October 28, 2015Research and Development, Sales and Marketing Cancer, GX Pharmaceuticals, Otsuka, Sativex, cancer pain, palliative care, phase III, phase III failure
Otsuka and GW Pharmaceuticals cannabis-based drug Sativex failed to show superiority over placebo in two Phase III trials.The studies were …
World’s largest clinical trial of aspirin in cancer launches in UK
October 22, 2015Research and Development CRUK, Cancer, Cancer Research UK, aspirin, clinical trial, phase III
The world’s largest ever clinical trial has been launched across the UK today, to discover whether taking aspirin every day …
Merck and Incyte to initiate Keytruda, epacadostat combo trial
October 15, 2015Research and Development Incyte, Merck, R&D, melanoma, phase III, skin cancer
Merck and biopharma firm Incyte are to expand their clinical collaboration to include a Phase III study evaluating the combination …
Lilly shares fall as company abandons evacetrapib development
October 13, 2015Manufacturing and Production evacetrapib, high cholesterol, lilly, phase III, phase III failure
Eli Lilly shares fell by nearly 8% this week as the company announced it will abandon developmenty of the investigational …
UCB plots new Vimpat submissions after positive monotherapy results
October 8, 2015Research and Development EMA, European Medicines Agency, UCB, carbamazepine, epilepsy, lacosamide, phase III, vimpat
A Phase III non-inferiority study comparing UCB’s Vimpat with carbamazepine suggests the two drugs can be used as monotherapy treatments. …
GSK suffers Breo late-stage trial blow
September 9, 2015Research and Development COPD, GSK, Revlar, asthma, breo, clinical trial, phase III
GSK has hit a setback in its plans to expand sales of its blockbuster asthma treatment Breo, after a major …
Mixed Phase 3 results for Sanofi and UCB
July 29, 2015Research and Development LixiLan, Sanofi, UCB, clinical trials, epratuzumab, insulin, insulin glargine, phase III
Two drugs that pharma companies are pinning hopes on for future success have had mixed outcomes in key late-stage clinical …
Novo Nordisk pushes forward with new diabetes drug trial
July 13, 2015Research and Development GLP-1 agonist, Novo Nordisk, diabetes, phase III, semaglutide, type 2 diabetes
Novo Nordisk is taking the first steps towards adding another type 2 diabetes drug to its portfolio, after announcing positive …
GSK cancer vaccine fails in Phase III
September 5, 2013Research and Development, Sales and Marketing BMS, GSK, Yervoy, melanoma, phase III
GlaxoSmithKline’s hopes of creating a cancer vaccine against the deadliest form of skin cancer took a blow today when its …
GSK severe asthma drug progresses to Phase III
August 20, 2012Research and Development, Sales and Marketing Advair, GSK, Phase II, asthma, phase III
GlaxoSmithKline’s severe asthma drug mepolizumab has impressed in a mid-stage study, meaning it can now progress into Phase III testing. …
immatics’ vaccine increases survival in kidney cancer
July 30, 2012Research and Development, Sales and Marketing IMA901, Vaccine, Yervoy, immatics, phase III
immatics’ investigational cancer vaccine has increased survival rates in patients with renal cell carcinoma. In a late-stage trial, the German …
Bayer cancer drug meets Phase III goal
April 3, 2012Research and Development, Sales and Marketing Bayer, Cancer, Glivec, Novartis, phase III, regorafenib
Bayer’s stomach cancer pill regorafenib has significantly improved progression free survival in late-stage patients. Results from the Phase III trial …
Encouraging data for Eisai epilepsy drug
August 24, 2010Sales and Marketing Eisai, epilepsy, perampanel, phase III, seizures, study 306
A new phase III study for Eisai’s perampanel (E2007) suggests the first-in-class treatment is effective as an adjunctive treatment of …
Daiichi’s lung cancer drug progresses to phase III
August 5, 2010Research and Development Daiichi, arq 197, arqule, lung cancer, phase III
Daiichi Sankyo and biotech firm Arqule are to move their lung cancer treatment ARQ 197 into phase III trials. The …
Latest content
Five Facts about cardiovascular disease
